2022-05-04| Special

Spero Therapeutic Lays Off 75% of Employees Resulting in Stock Plummet

by Reed Slater
Share To

Spero Therapeutics, a Massachusetts-based biopharmaceutical company, announced on May 3 that it will lay off 75% of its workforce after a discussion with the Food and Drug Administration regarding its New Drug Application for tebipenem HBr, an oral carbapenem antibiotic to treat complicated urinary tract infections (cUTI). While the FDA has not formally rejected the application yet, Spero, sensing the impending dismissal, decided to thin its personnel, resulting in its stock plummeting to the lowest point in its history. 


The Project Responsible: Tebipenem HBr


Spero’s primary product candidate for several years running was Tebipenem HBr which went through Phase 3 clinical trials. Tebipenem HBr is designed to use carbapenem antibiotics in oral form to help patients dealing with cUTI transition from intravenous injected carbapenem antibiotics in the hospital to an oral treatment at home. Currently, carbapenem antibiotics are only available in intravenous injection form. 

It's free! Log in now to read

From Sweet to Risky: The Alarming Findings on Sucralose’s Genotoxicity
GHG Emissions as a ESG Metric
NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day
Krystal Biotech’s First Topical Gene Therapy Approved by FDA
The Emergence of General AI for Medicine: Medical Applications of ChatGPT
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
2023 International Healthcare Week: Showcasing Emerging Competencies of Hong Kong’s Biomedical Industry
Scroll to Top